Royalty Pharma plc (FRA:RPD)
Germany · Delayed Price · Currency is EUR 31.75
+0.49 (1.57%)
At close: Jul 29, 2025, 10:00 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Revenue from Intangible Royalty Assets | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue from Intangible Royalty Assets Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Royalty Income | - | Log In | Log In | Log In | Log In | Upgrade |
Other Royalty Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Cystic Fibrosis Franchise | 826.21M | Log In | Log In | Log In | Log In | Upgrade |
Cystic Fibrosis Franchise Growth | -7.09% | Log In | Log In | Log In | Log In | Upgrade |
Tysabri | 124.82M | Log In | Log In | Log In | Log In | Upgrade |
Tysabri Growth | -20.92% | Log In | Log In | Log In | Log In | Upgrade |
Imbruvica | 131.09M | Log In | Log In | Log In | Log In | Upgrade |
Imbruvica Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Xtandi | - | Log In | Log In | Log In | Log In | Upgrade |
Xtandi Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Promacta | - | Log In | Log In | Log In | Log In | Upgrade |
Promacta Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Tazverik | - | Log In | Log In | Log In | Log In | Upgrade |
Other Products | 548.82M | Log In | Log In | Log In | Log In | Upgrade |
Other Products Growth | 8.65% | Log In | Log In | Log In | Log In | Upgrade |
Tremfya | 147.14M | Log In | Log In | Log In | Log In | Upgrade |
Tremfya Growth | 1.87% | Log In | Log In | Log In | Log In | Upgrade |
Trelegy | 146.92M | Log In | Log In | Log In | Log In | Upgrade |
Trelegy Growth | 13.04% | Log In | Log In | Log In | Log In | Upgrade |
Evrysdi | 224.43M | Log In | Log In | Log In | Log In | Upgrade |
Evrysdi Growth | 63.90% | Log In | Log In | Log In | Log In | Upgrade |
Other Royalty Income and | 114.15M | Log In | Log In | Log In | Log In | Upgrade |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Portfolio Receipts | 2.80B | Log In | Log In | Log In | Log In | Upgrade |
Portfolio Receipts Growth | 17.06% | Log In | Log In | Log In | Log In | Upgrade |